<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4769">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01786902</url>
  </required_header>
  <id_info>
    <org_study_id>DA3002_ISS_III</org_study_id>
    <nct_id>NCT01786902</nct_id>
  </id_info>
  <brief_title>Idiopathic Short Stature Study</brief_title>
  <official_title>Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Short Stature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea : Korea Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growth hormone therapy will improve the height of idiopathic short statured children.
      DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to
      non-treatment group in efficacy and safety.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The difference of annualized height velocity between treatment group and non-treatment group after 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of Height Standard Deviation Score between treatment and non-treatment group after 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The change of antibodies to growth hormone</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Idiopathic Short Stature</condition>
  <arm_group>
    <arm_group_label>DA-3002 Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.11 IU(0.37mg)/kg bodyweight of DA-3002 per week given by subcutaneous injections (six or seven times per week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-treatment control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Height be measured with no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-3002</intervention_name>
    <arm_group_label>DA-3002 Treatment group</arm_group_label>
    <other_name>Recombinant Human Growth Hormone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronological Age â‰¥ 4

          -  Bone Age &lt;11 (for girls) and &lt;13 (for boys)

          -  Height &lt;3rd percentile for age

          -  normal thyroid function

        Exclusion Criteria:

          -  endocrine and/or metabolic disorders

          -  growth failure caused by other disorders

          -  previous use of drugs that could interfere with Growth Hormone treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanwook Yoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byungkyu Suh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheolwoo Ko, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keehyoung Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Korea University Anam Hospitial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dongkyu Jin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choongho Shin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinsoon Hwang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aju University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hoseong Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Severance Children's Hospital Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wooyoung Jeong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pusan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chanjong Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heonsuk Han, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chungbuk National University</affiliation>
  </overall_official>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 12, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>growth hormone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
